Which are the evidences of the use of probiotics in gastroenterology?;Impiego dei probiotici in gastroenterologia: Quali evidenze?

Argomenti di Gastroenterologia Clinica

Volumn 19, Issue 2, 2006, Pages 31-39

  Moretti, Alessandra ^a   Papi, Claudio ^a   Koch, Maurizio ^a   Capurso, Lucio ^a  

^a SAN FILIPPO NERI HOSPITAL   (Italy)

Author keywords

Diarrhea; Gastrointestinal disorders; Inflammatory bowel disease; Irritable bowel syndrome; Probiotics

Indexed keywords

PROBIOTIC AGENT;

BIFIDOBACTERIUM; CROHN DISEASE; DIARRHEA; ENTERITIS; EVIDENCE BASED MEDICINE; GASTROINTESTINAL DISEASE; HELICOBACTER PYLORI; IRRITABLE COLON; LACTOBACILLUS; MEDICAL PRACTICE; REVIEW; ULCERATIVE COLITIS;

EID: 33745927438     PISSN: 11208651     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Guamer F, Schaafsma GJ. Probiotics. Int J Food Microbiol 1998;39:237-8.
2. Hurley BW, Nguyen CC. The spectrum of pseudomembranous enterocolitis and antiobiotic associated diarrhea. Arch intern Med 2002;162:2177-84.
3. Bartlett JG. Antibiotic-associated diarrhea. New Engl J Med 2002;346:334-9.
4. D'Souza AL, Rajkumar C, Cooke J, Bulpitt CJ et al. Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis BMJ 2002;324:1361.
5. Hurley BW, Nguyen CC. The spectrum of pseudomembranous enterocolitis and antiobiotic associated diarrhea. Arch intern Med 2002;162:2177-84.
6. Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med 1994;330:257-62.
7. Fekety R. Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 1997;92:739-50.
8. McFarland LV, Surawicz CM, Greenberg FW et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994;271:1913-8.
9. Surawicz CM, McFarland LV, Greenberg RN et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose Vancomycin combined with Saccharomyces boulardii. Clinical Infectious Diseases 2000;31:1012-7.
10. McFarland LV, Surawicz CM, Greenberg RN et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994;271:1913-8.
11. Baqui AH, Black RE, Sack RB et al. Malnutrition, cell-mediated immune deficiency, and diarrhea: a community-based longitudinal study in rural Bangladeshi children. Am J Epidemiol 1993;137:355-65,
12. Guarino A, Canani RB, Spagnuolo MI et al. Oral bacterial therapy reduces the duration of symptoms and of viral excretion in children with mild diarrhea. J Pediatr Gastroenterol Nutr 1997;25:516-9.
13. Van Niel CW, Feudtner C, Garrison MM et al. Lattobacillus therapy for acute infections diarrhea in children: a meta-analysis. Pediatrics 2002;109:678-84.
14. King TS, Elia M, Hunter JO. Abnormal colonic fermentation in irritable bowel syndrome. Lancet 1998;352:1187-9.
15. Cummgs JH, Macfarlane GT. The control and consequences of bacterial fermentation in the human colon. J Appl Bacteriol 1991;70:443-59.
16. Cummgs JH, Engryst HN. Fermentation in the human large intestine. Am J Clin Nutrit 1987;45:1243-55.
17. Balsari A, Ceccarelli A, Dubini F et al. The fecal microbial population in the irritable bowel syndrome Microbiologica 1982;5:185-94.
18. Madden JA, Hunter JO. A review of the role of the gut microflora in irritable bowel syndrome and the effects of probiotics. Br J Nutr 2002;88(Suppl 1):S67-72.
19. Collins MD, Gibson GR. Probiotics, prebiotics, and synbiotics: approaches for modulating the microbial ecology of the gut. Am J Clin Nutr 1999;69:1052S-7S.
20. Barbara G, De Giorgio R, Stangheilini V et al. A role for inflammation in irritable bowel syndrome? Gut 2002;51(Suppl 1): 41-4.
21. Halpem GM, Prindivilie T, Blankenburg M et al. Treatment of irritable bowel syndrome with Lacteol Fort: a randomized, double-blind, cross-over trial. Am J Gastroenteral 1996;91:1579-85.
22. O'Sullivan MA, O'Morain CA. Bacterial supplementation in the irritable bowel syndrome. A randomised double-blind placebo-controlled crossover study. Digest Liver Dis 2000;32:2114-301.
23. Nobaek S, Johansson ML, Molin G et al. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenter 2000;95:1231-9.
24. Niedzielin K, Kordecki H, Birkenfeld B. A controlled, double-blind, randomized study on the efficacy of Lactobacillus plarrtamm 299V in patients with irritable bowel syndrome. Eur J Gastroenter Hepatol 2001;13:1143-7.
25. Sen S, Mullan MM, Parker TJ et al. Effect of lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome. Dig Dis Sci 2002;47:2615-20.
26. Kim HJ, Camilleri M, Mckinzie S et al. A randomized controlled trial of a probiotic, VSL3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2003;17:895-904.
27. Saggioro A. Probiotics in the treatment of irritable bowel syndrome. J Clin Gastroenterol 2004;38:S104-6.
28. Veldhuyzen van Zanten SJ, Talley NJ, Bytzer P et al. Design of treatment trials for functional gastrointestinal disorders. Gut 1999;45:69-77.
29. Kabir AM, Aiba Y, Takagi A et al. Prevention of Helicobacter pylori infection by lactobacilli in a gnotobiotic murine model. Gut 1997;41:49-55.
30. Coconnier MH, Lievin V, Hemery E et al. Antagonistic activity against Helicobacter infection in vitro and in vivo by the human Lactobacillus acidophilus strain LB Appl Environ Microbiol 1998;64:4573-80.
31. Mukai T, Asasaka T, Sato E et al. Inhibition of binding of Helicobacter pylori to the gtycolipid receptors by probiotic Lactobacillus reuteri. EMS Immunol Med Microbiol 2002;32:105-10.
32. Midolo PO, Lambert JR, Hull R et al. In vitro inhibition of Helicobacter pylori NCTC 11637 by organic acids and lactic acid bacteria. J Appl Bacteriol 1995;79:475-9.
33. Aiba Y, Suzuki N, Kabir AM et al. Lactic acid-mediated suppression of Helicobacter pylori by the oral administration of Lactobacillus salivarius as a probiotic in a gnotobiotic murine model. Am J Gastroenterol 1998;93:2097-101.
34. Lorca GL, Wadstrom T, Valdez GF et al. Lactobacillus acidophilus autolysins inhibit Helicobacter pylori in vitro. Curr Microbiol 2001;42:39-44.
35. Canducci F, Armuzzi A, Cremonini F et al. A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates. Aliment Pharmacol Ther 2000;14:1625-9.
36. Sheu BS, Wu JJ, Lo CY et al. Impact of supplement with Lactobacillus- and Bifidobacterium-containing yogurt on triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2002;16:1669-75.
37. Armuzzi A, Cremonini F, Bartotozzi F et al. The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther 2001;15:163-9.
38. Cremonini F, Di Caro S, Covino M et al. Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol 2002;97:2744-9.
39. Nista EC, Candelli M, Cremonini F et al. Bacillus dausii therapy to reduce side-effects of anti-Helicobacter pylori treatment: randomized, double-blind, placebo controlled trial. Aliment Pharmacol Ther 2004;20:1181-8.
40. Janowitz HD, Croen EC, Sachar DB. The role of the fecal stream in Crohn's disease: an historical and analytic review. Inflam Bowel Dis 1998;4:29-39.
41. Rutgeerts P, Goboes K, Peeters M et al. Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet 1991;338:771-4.
42. Swidsinski A, Ladhoff A, Pemthaler A et al. Mucosal flora in inflammatory bowel disease. Gastroenterology 2002;122:44-54.
43. Fabia R, Ar'Rajab A, Johansson ML et al. Impairment of bacterial flora in human ulcerative colitis and experimental colitis in the rat Digestion 1993;54:248-55.
44. Boudeau J, Glasser AL, Julien S et al. Inhibitory effect of probiotic Escherichia coli strain Nissle 1917 on adhesion to and invasion of intestinal epithelial cells by adherent-invasive E. coli strains isolated from patients with Crohn's disease. Aliment Pharmacol Ther 2003;18:45-56.
45. Borruel N, Carol M, Casellas F et al. Increased mucosal tumour necrosis factor alpha production in Crohn's disease can be downregulated ex vivo by probiotic bacteria. Gut 2002;51:659-64.
46. Malchow HA. Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease? J Clin Gastroenterol 1997;25:653-8.
47. Guslandi M, Mezzi G, Sorghi W et al. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 2000;45:1462-4.
48. Plantera C, Scribano ML, Falasco G et al. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut 2002;51:405-9.
49. Campieri M, Rizzello F, Venturri A et al. Combination of antibiotic and probiotic treatment is efficious in prophylaxis of post-operative recurrence of Crohns disease: a randomized controlled study vs mesalazine. Gastroenterology 2001;118:A781.
50. Ruperts P, Hiele M, Geboes K et al. Controlled trial of metronidazole treatmert for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995;108:1617-21.
51. Verturi A, Gionchetti P, Rizzello F et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis Aliment Pharmacol Ther 1999;13:1103-8.
52. Kruis W, Schutz E, Fric P et al. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997;11:853-8.
53. Rembacken BJ, Snelling AM, Hawkey PM et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999;354:635-9.
54. Kruis W, Fric P, Pokrotnieks J et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004;53:1617-23.
55. Gionchetti P, Rizzello F, Helwig U et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003;124:1202-9.
56. Gionchetti P, Rizzello F, Venturi A et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000;119:305-9.
57. Mimura T, Rizzello F, Helwig U et al. Once daily high dose probiotic therapy (VSL3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004;53:108-14.